DZ Bank’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $237M | Sell |
1,091,285
-7,827,781
| -88% | -$1.74B | 0.21% | 94 |
|
|
2025
Q4 | $2.04B | Buy |
8,919,066
+2,424,561
| +37% | +$552M | 1.76% | 10 |
|
|
2025
Q3 | $1.5B | Buy |
6,494,505
+1,771,612
| +38% | +$361M | 1.32% | 10 |
|
|
2025
Q2 | $877M | Buy |
4,722,893
+2,969,202
| +169% | +$552M | 0.88% | 27 |
|
|
2025
Q1 | $367M | Buy |
1,753,691
+383,291
| +28% | +$74.5M | 0.41% | 68 |
|
|
2024
Q4 | $244M | Sell |
1,370,400
-4,142,655
| -75% | -$762M | 0.25% | 80 |
|
|
2024
Q3 | $1.09B | Buy |
5,513,055
+72,005
| +1% | +$13.4M | 1.07% | 26 |
|
|
2024
Q2 | $933M | Sell |
5,441,050
-339,655
| -6% | -$56.3M | 0.96% | 26 |
|
|
2024
Q1 | $1.05B | Buy |
5,780,705
+2,305,248
| +66% | +$397M | 1.13% | 21 |
|
|
2023
Q4 | $539M | Sell |
3,475,457
-482,575
| -12% | -$70.4M | 0.67% | 40 |
|
|
2023
Q3 | $590M | Sell |
3,958,032
-469,655
| -11% | -$68.9M | 0.84% | 34 |
|
|
2023
Q2 | $597M | Sell |
4,427,687
-1,787,254
| -29% | -$262M | 0.9% | 26 |
|
|
2023
Q1 | $990M | Buy |
6,214,941
+1,253,058
| +25% | +$192M | 1.63% | 10 |
|
|
2022
Q4 | $802M | Buy |
4,961,883
+1,320,349
| +36% | +$202M | 1.4% | 19 |
|
|
2022
Q3 | $489M | Sell |
3,641,534
-1,957,339
| -35% | -$281M | 0.92% | 32 |
|
|
2022
Q2 | $858M | Sell |
5,598,873
-273,682
| -5% | -$41.8M | 1.54% | 14 |
|
|
2022
Q1 | $953M | Buy |
5,872,555
+331,289
| +6% | +$48.1M | 1.43% | 15 |
|
|
2021
Q4 | $753M | Buy |
5,541,266
+1,888,302
| +52% | +$223M | 1.07% | 24 |
|
|
2021
Q3 | $394M | Sell |
3,652,964
-2,115,954
| -37% | -$242M | 0.63% | 46 |
|
|
2021
Q2 | $650M | Buy |
5,768,918
+3,299,881
| +134% | +$372M | 1.06% | 30 |
|
|
2021
Q1 | $267M | Sell |
2,469,037
-1,894,334
| -43% | -$203M | 0.49% | 57 |
|
|
2020
Q4 | $460M | Buy |
4,363,371
+524,190
| +14% | +$50.4M | 0.97% | 26 |
|
|
2020
Q3 | $336M | Sell |
3,839,181
-122,204
| -3% | -$11.5M | 0.81% | 30 |
|
|
2020
Q2 | $389M | Buy |
3,961,385
+572,293
| +17% | +$50.4M | 1.07% | 24 |
|
|
2020
Q1 | $258M | Sell |
3,389,092
-665,017
| -16% | -$56.6M | 0.87% | 27 |
|
|
2019
Q4 | $359M | Buy |
4,054,109
+3,458,183
| +580% | +$287M | 0.94% | 26 |
|
|
2019
Q3 | $45.1M | Sell |
595,926
-314,124
| -35% | -$21.5M | 0.13% | 118 |
|
|
2019
Q2 | $66.2M | Buy |
910,050
+222,584
| +32% | +$17.5M | 0.2% | 95 |
|
|
2019
Q1 | $55.4M | Buy |
687,466
+95,255
| +16% | +$7.79M | 0.18% | 97 |
|
|
2018
Q4 | $54M | Sell |
592,211
-28,573
| -5% | -$2.51M | 0.21% | 105 |
|
|
2018
Q3 | $58.7M | Buy |
620,784
+33,148
| +6% | +$3.14M | 0.21% | 118 |
|
|
2018
Q2 | $54.5M | Buy |
587,636
+2,143
| +0.4% | +$209K | 0.2% | 117 |
|
|
2018
Q1 | $51.6M | Buy |
585,493
+101,879
| +21% | +$11.2M | 0.2% | 121 |
|
|
2017
Q4 | $46.8M | Buy |
483,614
+42,303
| +10% | +$3.99M | 0.18% | 127 |
|
|
2017
Q3 | $39.2M | Buy |
441,311
+7,715
| +2% | +$587K | 0.16% | 133 |
|
|
2017
Q2 | $31.4M | Sell |
433,596
-95,884
| -18% | -$6.45M | 0.15% | 143 |
|
|
2017
Q1 | $34.5M | Sell |
529,480
-132,484
| -20% | -$8.33M | 0.16% | 149 |
|
|
2016
Q4 | $41.5M | Buy |
+661,964
| New | +$40.4M | 0.2% | 135 |
|
Other funds holding ABBV
VCM
VPM
DZ Bank's ABBV Position: Q1 2026 in Review
DZ Bank reduced its AbbVie (ABBV) stake by 88% in Q1 2026, selling an estimated $1.74B and leaving 1,091,285 shares worth $237M. The position accounts for 0.21% of the portfolio, ranked #94.
DZ Bank first reported a position in ABBV in Q4 2016 and has held it in 38 quarters since. The position peaked at $2.04B in Q4 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- DZ Bank held 1,091,285 shares of AbbVie worth $237M as of Q1 2026.
- DZ Bank sold 7,827,781 AbbVie shares in Q1 2026, an estimated $1.74B.
- AbbVie made up 0.21% of DZ Bank's portfolio in Q1 2026, its #94 holding.
- DZ Bank first reported a position in AbbVie in Q4 2016 and has held it in 38 quarters since.
- DZ Bank's AbbVie position peaked at $2.04B in Q4 2025.
- 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on DZ Bank's 13F filing for Q1 2026, filed 15 May 2026.